Эффективность риск-адаптированной терапии острого миелоидного лейкоза у детей с использованием режимов интенсивного тайминга и трансплантации гемопоэтических стволовых клеток

Список литературы

1. Румянцев А.Г., Масчан А. А. Трансплантация гемопоэтических стволовых клеток у детей. «Медицинское информационное агентство», Москва, 2003
2. Савченко В.Г., Паровичникова Е. Н. Лечение острых лейкозов. «МЕДпресс-информ», Москва, 2004
3. Самочатова Е.В., Масчан А. А., Алейникова О. В. и др. Долгосрочные результаты комбинированного лечения острого промиелоцитарного лейкоза у детей и подростков с использованием генно-направленной терапии. Терапевтический архив (2007) 7:26−30
4. Флейшман Е.В., Сокова О. И., Криченко О. П. и др. Сложные аномалии кариотипа при остром миелоидном лейкозе у детей. Вестник Российской Академии Наук. 2008 5:3−7
5. Abbott B.L., Rubnitz J.E., Tong X. et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution’s experience. Leukemia (2003) 11:2090−2096
6. Aliff T.B., Maslak P.G., Jurcic J.G. et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer (2003) 4:1025−1032
7. Alter B.P. Bone marrow failure syndromes in children. Pediatric Clinics of North America (2002)5:973−988
8. Anaissie E.J. Diagnosis and therapy of fungal infection in patients with leukemia new drugs and immunotherapy. Best Practice & Research Clinical Haematology (2008) 4:683 690
9. Andersson B.S., Luna M.A., Yee C. et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer (1990) 5:1079−1084
10. Armendariz H., Barbieri M.A., Freigeiro D. et al. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials. Leukemia (2005) 12:2139−2142
11. Ascioglu S., Rex J.H., de Pauw B. et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases (2002) 1:7−14
12. Attar E.C., De Angelo D.J., Supko J.G. et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clinical Cancer Research (2008) 5:1446−1454
13. Bagby G.C., Alter B.P. Fanconi anemia. Seminars in Hematology (2006) 3:147−156
14. Barrios N.J., Tebbi C.K., Freeman A.I. et al. Toxicity of high dose Ara-С in children and adolescents. Cancer (1987) 2:165−169
15. Basu S.K., Fernandez I.D., Fisher S.G. et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. Journal of Clinical Oncology (2005) 31:7958−7966
16. Becton D., Dahl G.V., Ravindranath Y. et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood (2006) 4:1315−1324
17. Beghini A., Ripamonti C.B., Cairoli R. et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica (2004) 8:920−925
18. Bennett J.M., Catovsky D., Daniel M.T. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology (1976) 4:451−458
19. Bentires-Alj M., Paez J.G., David F.S. et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research (2004) 24:8816−8820
20. Bisschop M.M., Revesz Т., Bierings M. et al. Extramedullar infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia. Leukemia (2001) 1:46−49
21. Bleakley M., Lau L., Shaw P.J., Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplantation (2002) 10:843−852
22. Bloomfield C.D., Lawrence D., Byrd J.C. et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research (1998) 18:4173−4179
23. Blum W., Klisovic R.B., Hackanson B. et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology (2007) 25:3884−3891
24. Bohn G., Welte K., Klein C. Severe congenital neutropenia: new genes explain an old disease. Current Opinion in Rheumatolology (2007) 6:644−650
25. Boissel N., Leroy H., Brethon B. et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia (2006) 6:965−970
26. De Braekeleer M., Morel F., Le Bris M.J. et al. The MLL gene and translocations involving chromosomal band 1 lq23 in acute leukemia. Anticancer Research (2005) 3B:1931−1944
27. Breems D.A., Lowenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Seminars in Hematology (2007) 4:259−266
28. Brethon В., Auvrignon A., Galambrun C. et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer (2006) 6:172
29. Brethon В., Yakouben K., Oudot C. et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. British Journal of Haematology (2008) 4:541−547
30. Brown P., Mclntyre E., Rau R. et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood (2007) 3:979−985
31. Brunet A.S., Ploton C., Galambrun A. et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatric Blood and Cancer (2006) 6:765−772
32. Biichner Т., Berdel W.E., Haferlach C. et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology (2009) 1 :61−69
33. Buckley J.D., Chard R.L., Baehner R.L. et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer (1989) 8:1457−1465
34. Budde R. Enzyme and immunohistochemical studies on acute monocytic leukemia (FAB M5): proposal for a new immunohistochemical subclassification. Acta Haematologica (1996)2:102−106
35. Bullinger L., Rticker F.G., Kurz S. et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood (2007) 4:1291−1300
36. Burnett A.K. Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Cancer Chemotherapy Pharmacology (2001) 1:53−58
37. Burnett A.K., Wheatley K., Goldstone A.H. et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology (2002) 2:385−400
38. Byrd J.C., Weiss R.B. Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8−21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer (1994) 8:2107−2112
39. Caggiano V., Weiss R.V., Rickert T.S. et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer (2005) 9:1916−1924
40. Cairoli R., Beghini A., Grillo G. et al. Prognostic impact of c-KJT mutations in core binding factor leukemias: an Italian retrospective study. Blood (2006) 9:3463−3468
41. Callens C., Chevret S., Cayuela J.M. et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocyte leukemia (APL): a retrospective study from the European APL Group. Leukemia (2005) 7:1153−1160
42. Camus P., Costabel U. Drug-induced respiratory disease in patients with hematological diseases. Seminars in Respiratory and Critical Care Medicine (2005) 5:458−481
43. Carlsson G., Melin M., Dahl N. et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatrica (2007) 6:813−819
44. Cazin В., Gorin N.C., Jouet J.P. et al. Successful autologous bone marrow transplantation in second remission of malignant histiocytosis. Bone Marrow Transplantation (1990) 6:431−433
45. Chen A.R., Alonzo T.A., Woods W.G. et al. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?~an American view. British Journal of Haematology (2002) 2:378−384
46. Chi Y., Lindgren V., Quigley S., Gaitonde S. Acute myelogenous leukemia with t (6−9)(p23-q34) and marrow basophilia: an overview. Archives of Pathology and Laboratory Medicine (2008) 11:1835−1837
47. Chim C.S., Ooi C.G. The irreplaceable image: Cerebral leukostasis manifesting as multifocal intracerebral hemorrhage. Haematologica (2001) 11:1231
48. Chowdhury Т., Brady H.J. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. Blood Cells, Molecules and Diseases (2008) 2:192−199
49. Cohen J., Brun-Buisson C., Torres A. et al. Diagnosis of infection in sepsis: an evidence-based review. Critical Care Medicine (2004) 11:466−494
50. Cortes J., Giles F., O’Brien S. et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer (2003) 11:2760−2766
51. Creutzig U., Ritter J., Budde M. et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer (1987) 12:3071−3079
52. Creutzig U., Harbott J., Sperling C. et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood (1995) 8:3097−3108
53. Creutzig U., Zimmermann M., Ritter J. et al. Definition of a standard-risk group in children with AML. British Journal of Haematology (1999) 3:630−639
54. Creutzig U., Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? a European view. British Journal of Haematology (2002) 2:365−377
55. Creutzig U., Zimmermann M., Ritter J. et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia (2005) 12:20 302 042
56. Dale D.C. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs (2002) 1:1−15
57. Del Poeta G., Bruno A., Del Principe M.I. et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Current Cancer Drug Targets (2008) 3:207−222
58. Delaunay J., Vey N., Leblanc T. et al. Prognosis of inv (16)/t (16−16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood (2003) 2:462−469
59. Dillman R.O., Davis R.B., Green M.R. et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood (1991) 10:2520−256
60. Dixon N., Kishnani P. S., Zimmerman S. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics (2006) 3:149−157
61. Dohner K., Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica (2008) 7:976−982
62. Doepfner K.T., Boiler D., Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Critical Reviews in Oncology / Hematology (2007) 3:215−230
63. Dusenbery K., Howells W.B., Arthur D.C. et al. Extramedullar leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group. Journal of Pediatric Hematology Oncology (2003) 10:760−768
64. Estey E.H., Pierce S., Keating M.J. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica (2000) 3:246−249
65. Estey E.H., Thall P.F., Wang X. et al. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood (2003) 9:3097−3099
66. Faber J., Armstrong S.A. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Research (2007) 18:8425−8428
67. Faderl S., Gandhi V., Kantarjian H.M. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Current Opinion in Hematology (2008) 2:101−107
68. Fagioli F., Zecca M., Locatelli F. et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. Journal of Pediatric Hematology Oncology (2008) 8:575−583
69. Falini В., Nicoletti I., Martelli M.F. et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood (2007)3:874−885
70. Fefer A., Robinson N., Benyunes M.C. et al. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer Journal Science America (1997) 1:48−53
71. Feig S.A., Lampkin В., Nesbit M.E. et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children’s Cancer Group. Bone Marrow Transplantation (1993) 1:65−71
72. Ferrara F., Del Vecchio L. Acute myeloid leukemia with t (8−21)/AMLl/ETO: a distinct biological and clinical entity. Haematologica (2002) 3:306−319
73. Feuring-Buske M., Frankel A., Gerhard B. et al. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Experimental Hematology (2000) 12:1390−1400
74. Fiedler W., Serve H., Dohner H. et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2005) 3:986−993
75. Fonatsch C., Gudat H., Lengfelder E. et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv (3)(q21q26) or t (3−3)(q21-q26). Leukemia (1994) 8:13 181 326
76. Frederick A.M., Davis M.L., Rice K.P. Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine. Biochemical and Biophysical Research Communications (2008) Nov 19 Пока доступна только электронная публикация.
77. Gale К.В., Ford A.M., Repp R. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proceedings of the National Academy of Sciences of the USA (1997) 25:13 950−13 954
78. Gassas A., Afzal S., Ishaqi M.K. et al., Doyle J. Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not? Bone Marrow Transplantation (2008) 6:393−396
79. Gibson B.E., Wheatley К., Hann I.M. et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia (2005) 12:2130−2138
80. Giles F.J., Keating A., Goldstone A.H. et al. Acute myeloid leukemia. Hematology (American Society of Hematology Education Program Book) (2002):73-l 10
81. Giles F., Verstovsek S., Faderl S. et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research (2006) 12:1591−1595
82. Glass J.P., Van Tassel P., Keating M.J. et al. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology (1987) 4:639−644
83. Glockner A., Steinbach A., Vehreschild J.J. et al. Treatment of invasive candidiasis with echinocandins. Mycoses (2008) Пока доступна только электронная публикация.
84. Gohring G., Karow A., Steinemann D. et al. Chromosomal aberrations in congenital bone marrow failure disorders—an early indicator for leukemogenesis? Annals of Hematology (2007) 10:733−739
85. Goldstein В., Giroir В., Randolph A. et al. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatric Critical Care Medicine (2005) 1:2−8
86. Gore S.D., Baylin S., Sugar E. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research (2006) 12:6361−6369
87. Gore S.D., Hermes-DeSantis E.R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control (2008) 15:40−49
88. Grafone Т., Palmisano M., Nicci C. et al. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells. Hematoljgy Oncology (2008) 3:159−166
89. Greaves M. Pre-natal origins of childhood leukemia. Reviews in Clinical and Experimental Hematology (2003) 3:233−245
90. Grier H.E., Gelber R.D., Clavell L.A. et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematology and Blood Transfusion (1990) 33:193−197
91. Guiot H.F., Peters W.G., van den Broek P.J. et al. Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection (1990) 3:131−137
92. Haferlach Т., Gassmann W., Loftier H. et al. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. Annals of Hematology (1993)4:165−170
93. Haferlach C., Dicker F., Herholz H., et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia (2008) 8:1539−1541
94. Hama A., Yagasaki H., Takahashi Y. et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. British Journal of Haematology (2008) 5:552−561
95. Harm I.M., Webb D.K., Gibson B.E. et al. MRC trials in childhood acute myeloid leukaemia. Annals of Hematology (2004) 1:108−112
96. Hasle H., Alonzo T.A., Auvrignon A. et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood (2007) 11:4641−4647
97. Haupt H.M., Hutchins G.M., Moore G.W. Ara-С lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. American Journal of Medicine (1981)2:256−261
98. Heibert S.W., Lutterbach В., Durst K. et al. Mechanisms of transcriptional repression by the t (8−21)-, t (12−21)-, and inv (16)-encoded fusion proteins. Cancer Chemotherapy Pharmacology (2001) 1:31−34
99. Heil G., Hoelzer D., Sanz M.A. et al. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia (2006) 3:404−409
100. Hollink I.H., Zwaan C.M., Zimmermann M. et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2008 Nov 20. Пока доступна только электронная публикация.
101. Но viand R., Gjertsen В.Т., Bruserud О. et al. Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. Leukemia and Lymphoma (2002) 10:2027−2029
102. Hunter H.M., Pallis M., Seedhouse C.H. et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. British Journal of Haematology (2004) 1:26−33
103. Hurwitz C.A., Schell M.J., Pui C.H. et al. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Medical and Pediatric oncology 1993(1): 1−7
104. Ichikawa H., Tanabe K., Mizushima H. et al. Common gene expression signatures in t (8−21) — and inv (16)-acute myeloid leukaemia. British Journal of Haematology (2006) 3:336−347
105. Imai N., Shikami M., Miwa H. et al. t (8−21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. British Journal of Haematology (2006) 5:673−682
106. Inaba H., Fan Y., Pounds S. et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer (2008)3:522−529
107. Issa J.P., Garcia-Manero G., Giles F.J. et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 5:1635−1640
108. Issa J.P. DNA methylation as a therapeutic target in cancer. Clinical Cancer Research (2007) 6:1634−1637
109. Iwai Т., Yokota S., Nakao M. et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children’s Cancer and Leukemia Study Group, Japan. Leukemia (1999) 1:38−43
110. Jaffe S., Harris N.L., Stein H., Vardiman J.W. Pathology and genetics of tumours of haematopoetic and lymphoid tissues (World Health Organisation Classification of Tumours). 2001, Lion, IARC Press (монография)
111. Jaju R.J., Haas O.A., Neat M. et al. A new recurrent translocation, t (5-ll)(q35-pl5.5), associated with del (5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG). Blood (1999) 2:773−780
112. Jeha S., Gandhi V., Chan K.W. et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 3:784−789
113. Jing Y. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leukemia and Lymphoma (2004) 4:639−648
114. Kahn J.N., Hsu M.J., Racine F. et al. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrobial Agents and Chemotherapy (2006) 6:2214−2216
115. Kaminsky D.A., Hurwitz C.G., Olmstead J.I. Pulmonary leukostasis mimicking pulmonary embolism. Leukemia Research (2000) 2:175−178
116. Kantarjian H.M., O’Brien S., Cortes J. et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer (2003) 3:522−528
117. Kantarjian H., O’Brien S., Cortes J. et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 7:1933−1952
118. Kardos G., Zwaan C.M., Kaspers G.J. et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia (2005) 12:2063−2071
119. Karp J. Acute myelogenous leukemia. 2007, Totowa, Humana Press (монография)
120. Karp J.E., Kaufmann S.H., Adjei A.A. et al. Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology (2001) 6:470−476
121. Karp J.E., Smith B.D., Gojo I. et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clinical Cancer Research (2008) 10:3077−3082
122. Kaspers G.J., Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia (2005) 12:2025−2029
123. Kaspers G.J., Zwaan C.M. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica (2007) 11:1519−1532
124. Keating M.J., Smith T.L., Kantarjian H. et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia (1988) 7:403−4012
125. Kimby E., Nygren P., Glimelius B. et al. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncologica (2001) 2−3:231−252
126. Kindler T,. Breitenbuecher F., Marx A. et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 10:3644−3654
127. Kiyoi H., Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. International Journal of Hematology (2006) 4:301−308
128. Klingebiel Т., Reinhardt D., Bader P. et al. Place of HSCT in treatment of childhood AML. Bone Marrow Transplantation (2008) 2:7−9
129. Knapp K.M., Flynn P.M. Newer treatments for fungal infections. Journal of Supportive Oncology (2005) 4:290−298
130. Kobayashi R., Tawa A., Hanada R. et al. Extramedullar infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatric Blood and Cancer (2007) 4:393−398
131. Kondo M., Horibe K., Takahashi Y. et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Medical and Pediatric Oncology (1999) 6:525−529
132. Krance R.A., Hurwitz C.A., Head D. et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. Journal of Clinical Oncology (2001) 11:2804−2811
133. KudererN.M., Dale D.C., Crawford J. et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 10:2258−2266
134. Lange B.J., Smith F.O., Feusner J. et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood (2008) 3:1044−1053
135. Laws H.J., Ammann R.A., Lehrnbecher T. Fieber unklarer Genese (FUO) bei Kindern und Jugendlichen mit onkologischen Erkrankungen. Klinische Padiatrie (2005) 1 1:9−16
136. Lehrnbecher Т., Varwig D., Kaiser J. et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia (2004) 1:72−77
137. Levy M.M., Fink M.P., Marshall J.C. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Medicine (2003) 4:530−538
138. Liang D.C. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatric Drugs (2003) 10:673−684
139. Lie S.O., Abrahamsson J., Clausen N. et al. Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia (2005) 12:20 902 100
140. Linabery A.M., Blair C.K., Gamis A.S. et al. Congenital abnormalities and acute leukemia among children with Down syndrome: a Children’s Oncology Group study. Cancer Epidemiology Biomarkers and Prevention (2008) 10:2572−2577
141. Linker C.A. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation (2003) 9:731−738
142. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001 Dec l-98(12):3212−20.
143. Lo-Coco F., Cuneo A., Pane F. et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica (2008) 7:1017−1024
144. Lowenberg В., Griffin J.D., Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (American Society of Hematology Education Program Book) (2003):82−101.
145. Loges S., Tinnefeld H., Metzner A. et al. Downregulation of VEGF-A, STAT5 and АКТ in acute myeloid leukemia blasts of patients treated with SU5416. Leukemia and Lymphoma (2006) 12:2601−2609
146. Lu D., Nounou R., Beran M. et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer (2003) 2:441−449
147. Liibbert M., Wijermans P., Kunzmann R. et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British Journal of Haematology (2001) 2:349−357
148. Lyman G.H. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. Journal of the National Comprehensive Cancer Network (2005) 4:557−571
149. Lynch H.T., Weisenburger D.D., Quinn-Laquer B. et al. Family with acute myelocytic leukemia, breast, ovarian, and gastrointestinal cancer. Cancer Genetics and Cytogenetics (2002) 1:8−14
150. Malagola M., Martinelli G., Rondoni M. et al. Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? Blood (2005) 2:904−905
151. Mantadakis E., Samonis G., Kalmanti M. et al. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematologica (2008) 2:73−82
152. Marbello L., Ricci F., Nosari A.M. et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leukemia Research (2008)8:1221−1227
153. Margolin K.A., Negrin R.S., Wong K.K. et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunology Review (1997) 157:231−240
154. Marlton P, Keating M, Kantarjian H et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia (1995) 6:965−671
155. Marshall JC, Maier RV, Jimenez M et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Critical Care Medicine (2004) 11:51 326
156. Martinelli G., Iacobucci I., Paolini S. et al. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clinical Advances in Hematology and Oncology (2008)4:303−310
157. McMahon K.A., Hiew S.Y., Hadjur S. et al. Mil has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell (2007) 3:338−345
158. Meshinchi S., Stirewalt D.L., Alonzo T.A. et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood (2003) 4:1474−1479
159. Meshinchi S., Alonzo T.A., Stirewalt D.L. et al. Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 12:3654−3661
160. Meshinchi S., Stirewalt D.L., Alonzo T.A. et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood (2008) 10:4930−4933
161. Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Seminars in Oncology (2008) 4:365−377
162. Nabhan C., Tallman M.S. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia. Clinical Lymphoma (2002) 1:19−23.
163. Nabhan C., Rundhaugen L.M., Riley M.B. et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leukemia Resarch (2005) 1:53−57
164. Neudorf S., Sanders J., Kobrinsky N. et al. Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplantation (2007) 4:313−318
165. O’Farrell A.M., Foran J.M., Fiedler W. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical Cancer Research (2003) 15:5465−5476
166. Okamoto Y., Ribeiro R.C., Srivastava D.K. et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. Journal of Pediatric Hematology Oncology (2003) 9:696−703
167. Oki Y., Issa J.P. Review: recent clinical trials in epigenetic therapy. Reviews Recent Clinical Trials (2006) 2:169−182
168. Ortega J.J., Diaz de Heredia C., Olive T. et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica (2003) 3:290−299
169. Pagano L., Fianchi L., Leone G. Fungal pneumonia due to molds in patients with hematological malignancies. Journal of Chemotherapy (2006) 4:339−352
170. Palmblad J., Papadaki H.A. Chronic idiopathic neutropenias and severe congenital neutropenia. Current Opinion Hematology (2008) 1:8−14
171. Paschka P., Marcucci G., Ruppert A.S. et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8−21): a Cancer and Leukemia Group В Study. Journal of Clinical Oncology (2006) 24:3904−3911
172. Paulsson K., Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathologie Biologie (2007) 1:37−48
173. Penketh P.G., Baumann R.P., Ishiguro K. et al. Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species. Leukemia Research (2008) 10:1546−53
174. Perel Y., Auvrignon A., Leblanc T. et al. Maintenance therapy in childhood acute myeloid leukemia. Annals of Hematology (2004) 1:116−119
175. Pession A., Rondelli R., Basso G. et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia (2005) 12:2043−53.
176. Peterson B.A., Brunning R.D., Bloomfield C.D. et al. Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. American Journal of Medicine (1987) 3:464−470
177. Pinkel D., Woo S. Prevention and treatment of meningeal leukemia in children. Blood (1994)2:355−366
178. Poletti V., Salvucci M., Zanchini R. et al. The lung as a target organ in patients with hematologic disorders. Haematologica (2000) 8:855−864
179. Poletti V., Costabel U., Semenzato G. Pulmonary complications in patients with hematological disorders: pathobiological bases and practical approach. Seminars in Respiratory and Critical Care Medicine (2005) 5:439−444
180. Poppe В., Van Limbergen H., Van Roy N. et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genetics and Cytogenetics (2001) 1:39−42
181. Porcu P., Cripe L.D., Ng E.W. et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leukemia and Lymphoma (2000) 1−2:1−18
182. Porcu P., Farag S., Marcucci G. et al. Leukocytoreduction for acute leukemia. Therapeutic Apheresis and Dialysis (2002) 1:15−23
183. Poyart C., Morand P., Buzyn A. Etiology of bacterial infections in febrile neutropenic patients: the role of the laboratory in the diagnosis. Presse medicale (2004) 7:460−466
184. Prokocimer M., Unger R., Rennert H.S. et al. Pooled analysis of p53 mutations in hematological malignancies. Human Mutation (1998) 1:4−18
185. Pui Ch.-H. Treatment of acute leukemias. 2003, Totowa, Humana Press (монография)
186. Pui Ch.-H. Childhood leukemias. II Edition (2006), New York, Cambrige University Press (монография)
187. Pui C.H., Schrappe M., Ribeiro R.C. et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (American Society of Hematology Education Program Book) (2004): 118−1145
188. Puumala S.E., Ross J.A., Olshan A.F. et al. Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children’s Oncology Group. Cancer (2007) 9:2067−2074
189. Qadir M., O’Loughlin K.L., Fricke S.M. et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clinical Cancer Research (2005) 6:2320−2326
190. Quintana J., Advis P., Becker A. et al. Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results. Leukemia (2005) 12:2143−2146
191. Raimondi S.C., Chang M.N., Ravindranath Y. et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood (1999) 11:3707−3716
192. Ravindranath Y., Yeager A.M., Chang M.N. et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. New England Journal of Medicine (1996) 22:1428−1434
193. Ravindranath Y., Chang M., Steuber C.P. et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia (2005) 12:2101−2116
194. Ravoet C., Mineur P., Robin V. et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Annals of Hematology (2008) 11:881−885
195. Razzouk B.I., Raimondi S.C., Srivastava D.K. et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution’s experience. Leukemia (2001)9:1326−1330
196. Reid J.M., Pendergrass T.W., Krailo M.D. et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Research (1990) 20:6525−6528
197. Reilly J.T. Pathogenesis of acute myeloid leukaemia and inv (16)(pl3-q22): a paradigm for understanding leukaemogenesis? British Journal of Haematology (2005) 1:18−34
198. Ribeiro R.C., Razzouk B.I., Pounds S. et al. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children’s Research Hospital, from 1980 to 2000. Leukemia (2005) 12:2125−2129
199. Rice K.L., Licht J.D. HOX deregulation in acute myeloid leukemia. Journal of Clinical Investigation (2007) 4:865−868
200. Robert J. Clinical pharmacokinetics of idarubicin. Clinical Pharmacokinetics (1993) 4:275 288
201. Rubnitz J.E., Raimondi S.C., Tong X. et al. Favorable impact of the t (9-ll) in childhood acute myeloid leukemia. Journal of Clinical Oncology (2002) 9:2302−2309
202. Rubnitz J.E., Raimondi S.C., Halbert A.R. et al. Characteristics and outcome of t (8−21)-positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia (2002) 10:2072−2077
203. Rubnitz J.E., Lensing S., Zhou Y. et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer (2004) 7:1677−1684
204. Safaian N.N., Czibere A., Bruns I. et al. Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD (+) acute myeloid leukemia. Leukemia Research (2007) 2:348−350
205. Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist (2007) 2:2−6
206. Sanz M.A., Grimwade D., Tallman M.S. et al. Guidelines on the management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) Sep 23 Пока доступна только электронная публикация.
207. Schaffer A.A., Klein C. Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil? Current Opinion in Allergy and Clinical Immunology (2007) 6:481−494
208. Schnittger S., Kinkelin U., Schoch C. et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 5:796−804
209. Scholl C, Bansal D, Dohner К et al. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest. 2007 Apr- 117(4): 1037−48. Epub 2007 Mar 8.
210. Schwartsmann G., Fernandes M.S., Schaan M.D. et al. Decitabine (5-Aza-2-deoxycytidine- DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia (1997) 1: 28−31
211. Schwyzer R., Sherman G.G., Cohn R.J. et al. Granulocytic sarcoma in children with acute myeloblasts leukemia and t (8−21). Medical and Pediatric Oncolology (1998) 3:144−149
212. Shearer P., Katz J., Bozeman P. et al. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia. Cancer (1994) 7:1953−1958
213. Sigalotti L., Fratta E., Coral S. et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Journal of Cell Physiology (2007) 2:330−344
214. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006:178−84.
215. Smith F.O., Broudy V.C., Zsebo K.M. et al. Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group. Blood (1994) 3:847−852
216. Smith F.O., Alonzo T.A., Gerbing R.B. et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia (2005) 12:2054−2062
217. Smith B.D., Levis M., Beran M. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 10:3669−3776
218. Soriano A.O., Yang H., Faderl S. et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood (2007) 7:2302−2308
219. Stark В., Jeison M., Gabay L.G. et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. British Journal of Haematology (2004) 3:320−327
220. Staropoli JF. Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays (2008)8:719−727
221. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opinion on Biology Therapy (2008) 4:527−540
222. Steffen В., Muller-Tidow C., Schwable J. et al. The molecular pathogenesis of acute myeloid leukemia. Critical Reviews in Oncology (2005) 2:195−221
223. Stein AS, O’Donnell MR, Slovak ML et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. Journal of Clinical Oncology 2003 Feb 15−21(4):615−23.
224. Sternberg D.W., Licht J.D. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. Current Opinion in Hematology (2005) 1:7−13
225. Stone R.M., DeAngelo D.J., Klimek V. et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2005) 1:54−60
226. Stucki A., Rivier A.S., Gikic M. et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood (2001) 7:2121−2129
227. Sung L., Lange B.J., Gerbing R.B. et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood (2007) 10:35 323 539
228. Tallman M.S., Rowlings P.A., Milone G. et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood (2000) 4:1254−1258
229. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood (2005)4:1154−1163
230. Tang R., Faussat A.M., Perrot J.Y. et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BiomedCentral Cancer (2008) 8:51−53
231. Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica (2007) 1:81−94
232. Thomas X., Elhamri M., Chelghoum Y. et al. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. Annals of Hematology (2005) 6:376−382
233. Thomas X., Elhamri M. Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia. Bulletin du Cancer (2005) 3:227−238
234. Tosi P., Visani G., Ottaviani E. et al. Inv (16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. European Journal of Haematology (1998)3:161−165
235. Varon R., Schoch C., Reis A. et al. Mutation analysis of the Nijmegen breakage syndrome gene (NBS1) in nineteen patients with acute myeloid leukemia with complex karyotypes. Leukemia and Lymphoma (2003) 11:1931 -1914
236. Visani G, Bernasconi P., Boni M. et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia—analysis of 848 patients. Leukemia (2001) 6:903−909
237. Vormoor J., Ritter J. Creutzig U. et al. Acute myelogenous leukaemia in children under 2 years-experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group. British Journal of Cancer (1992) 18:63−67
238. Walsh T.J., Anaissie E.J., Denning D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases (2008) 3:327−360
239. Ward A.C., Dale D.C. Genetic and molecular diagnosis of severe congenital neutropenia. Current Opinion in Hematology (2009) 1:9−13
240. Wattel E., Preudhomme C., Hecquet B. et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood (1994) 9:31 483 157
241. Webb D.K., Harrison G., Stevens R.F. et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood (2001) 6:1714−1720
242. Weisberg E., Roesel J., Bold G. et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood (2008) 13:5161−5170
243. Weisser M., Haferlach С., Haferlach Т. et al. Advanced age and high initial WBC influence the outcome of inv (3) (q21q26)/t (3−3) (q21-q26) positive AML. Leukemia and Lymphoma. (2007) 11:2145−2151
244. Wells R.J., Woods W.G., Lampkin B.C. et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. Journal of Clinical Oncology (1993) 3:538−545
245. Whitman S.P., Ruppert A.S., Marcucci G. et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group В study. Blood (2007) 12:5164−5167
246. Wiernik P.H., Banks P.L., Case D.C. Jr. et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood (1992) 2:313−319
247. Willemze R., Suciu S., Mandelli F. et al. Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. Annals of Hematology (2004) 1:134.
248. Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood. 1996 Jun 15−87(12):4979−89.
249. Woods W.G., Neudorf S., Gold S. et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood (2001) 1:56−62
250. Woods W.G. Intensified induction therapy for children with AML. Annals of Hematology (2004) 1:119−120
251. Yang A.S., Doshi K.D., Choi S.W. et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Research (2006) 10:5495−5503
252. Yeager A.M., Kaizer H., Santos G.W. et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. New England Journal of Medicine (1986) 3:141−147
253. Yilmaz S., Oren H., Demircioglu F., Irken G. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols. Journal of Pediatric Hematology/Oncology (2008) 3:195−204
254. Yoo S.J., Park C.J., Jang S. et al. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. Leukemia and Lymphoma (2006) 9:1788−1793
255. Zwaan C.M., Reinhardt D., Corbacioglu S. et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood (2003) 10:3868−3871
256. ЖКТ желудочно-кишечный тракт
257. ИВЛ искусственная вентиляция лёгких1. КМ костный мозг1. ЛДГ лактат-дегидрогеназа1. ME международные единицымкл микролитр1. НЭК неэритроидые клетки
258. ОЛЛ острый лимфобластный лейкоз
259. ОМЛ острый миелоидный лейкоз
260. ППР полная продолжительная ремиссия1. ПХТ полихимиотерапия
261. РАН Российская Акадеия Наук
262. РДКБ Российская Детская Клиническая Больницаппг Республиканский Научно-Практический Центр Детской1. Онкологии и Гематологии
263. ТГСК трансплантация гемопоэтических стволовых клеток фру фНКЦ дгои Федеральный Научно-Клинический Центр Детской Гематологии, 1. Онкологии и Иммунологии
264. ФУВ РГМУ Факультет Усовершенствования Врачей Российского
265. Государственного Медицинского Университета
266. ЦНС центральная нервная система
267. AIEOP исследовательская группа Associazione Italiana Ematologia ed
268. Oncologia Pediatrica (Италия)1. AML острый миелолейкоз
269. AML 1 /ЕТО аномальный транскрипт при t (8 -21)1. Ага-С цитозин-арабинозид
270. Ara-СТР арабинофураназилцитозин трифосфатgp^ исследовательская группа Pediatric Oncology Group (США и1. Канада)
271. Capizzi консолидация 2 (Ага-С + L-asp) для всех больных
272. Capizzi+VP+Mit блок для пациентов, которые не получили НАМ до дня 18
273. CBF/MYH11 аномальный транскрипт при inv (16) или t (16−16)(pl2-q23)
274. CCG исследовательская группа Children’s Cancer Group (США)qCqq исследовательская группа Dutch Childhood Oncology group1. Нидерланды) del делеция1. Dnr даунорубицин
275. EFS Event-free-survival, бессобытийная выживаемость
276. EORTC European Organization for Research and Treatment of Cancerрдц франко-американо-британская (French American — British) классификация лейкозов
277. GATLA исследовательская группа Grupo Argentino de Tratamiento de la1. ucemia Aguda (Аргентина)
278. G-CSF гранулоцитарный колоние-стимулирующий фактор1. Gy Грей1. Hb Гемоглобин1. a идарубицин1.-2 интерлейкин-2inth inv1. ME1.asp Mit
279. MLL/AF4 MLL/AF9 MLL/ELL MLL/AF1 MLL/AF6 MLL/MLL1. MRC1. MSG1. NOPHO1. OS P1. PINDA
280. PML/RAR-a POG q+/-RFS Sa02 t1. VP1. ADE + HD ARA-C1. ADE-HAM
281. Relapse-free-survival, безрецидивная выживаемостьпоказатель насыщения тканей кислородомтранслокацияэтопозид